Unleashing a Lazarus Effect With Selpercatinib in a Never-Smoker Patient With Stage IV, Chemo-Immunotherapy Refractory, RET C630Y-Mutant, Small-Cell Lung Cancer: A First Case Report

JCO Precis Oncol. 2023 Sep:7:e2300321. doi: 10.1200/PO.23.00321.

Authors

Antonio Calles¹, Marta Arregui¹, Julia Suárez-González^{2

3}, María García-Martos⁴, Iván Márquez-Rodas^{1

5}, Rosa Álvarez¹, Miguel Martin^{1

3}

Affiliations

¹ Medical Oncology Department, Hospital General Universitario Gregorio Marañon, Madrid, Spain.
² Genomic Unit, Hospital General Universitario Gregorio Marañon, Madrid, Spain.
³ Instituto de Investigación Sanitaria Gregorio Marañon, Madrid, Spain.
⁴ Pathology Department, Hospital General Universitario Gregorio Marañon, Madrid, Spain.
⁵ Hereditary Familial Cancer Unit, Hospital General Universitario Gregorio Marañon, Madrid, Spain.

PMID: 37922409
DOI: 10.1200/PO.23.00321

No abstract available

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Lung Neoplasms* / drug therapy
Lung Neoplasms* / genetics
Proto-Oncogene Proteins c-ret / genetics
Pyrazoles
Pyridines
Small Cell Lung Carcinoma* / drug therapy
Small Cell Lung Carcinoma* / genetics
Smokers

Substances

selpercatinib
Pyrazoles
Pyridines
RET protein, human
Proto-Oncogene Proteins c-ret